

Resource Summary Report

Generated by [kravitz2](#) on Sep 19, 2026

B6.129-Kras^{tm4Tyj} Trp53/J

RRID:IMSR_JAX:032435

Type: Organism

Proper Citation

RRID:IMSR_JAX:032435

Organism Information

URL: <https://www.jax.org/strain/032435>

Proper Citation: RRID:IMSR_JAX:032435

Description: Mus musculus with name B6.129-Kras^{tm4Tyj} Trp53/J from IMSR.

Species: Mus musculus

Notes: gene symbol note: transformation related protein 53|Kras proto-oncogene; GTPase; mutant strain|congenic strain: Trp53|Kras

Affected Gene: transformation related protein 53|Kras proto-oncogene; GTPase

Genomic Alteration: targeted mutation 1; Anton Berns|targeted mutation 4; Tyler Jacks

Catalog Number: JAX:032435

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6.129-Kras^{tm4Tyj} Trp53/J

Record Creation Time: 20250513T053828+0000

Record Last Update: 20260919T055012+0000

Ratings and Alerts

No rating or validation information has been found for B6.129-Kras^{tm4Tyj} Trp53/J.

Warning: Warning. Researchers have noted that this genotype does not sufficiently model human acute myeloid leukemia.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Ghosh S, et al. (2026) Chemokine-defined macrophage niches establish spatial organization of tumor immunity. *Nature immunology*, 27(4), 715.

Cararo Lopes E, et al. (2025) Respiration defects limit serine synthesis required for lung cancer growth and survival. *Nature communications*, 16(1), 7621.

Schneider JL, et al. (2025) GUK1 activation is a metabolic liability in lung cancer. *Cell*, 188(5), 1248.

Hegde S, et al. (2025) Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours. *Nature*, 646(8087), 1214.

Li Q, et al. (2025) Long noncoding RNA-dependent control of Myc transcriptional bursting. *Cell reports*, 44(10), 116439.

Bleve A, et al. (2025) ROR γ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression. *Cancer discovery*, 15(7), 1505.

Mandula JK, et al. (2024) Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. *Immunity*, 57(5), 1124.

Hänggi K, et al. (2024) Interleukin-1 β release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. *Cancer cell*, 42(12), 2015.

Zhuo Y, et al. (2022) Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway. *Journal for immunotherapy of cancer*, 10(5).

Jia Y, et al. (2021) Crosstalk between hypoxia-sensing ULK1/2 and YAP-driven glycolysis fuels pancreatic ductal adenocarcinoma development. *International journal of biological sciences*, 17(11), 2772.

Srivastava S, et al. (2021) Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. *Cancer cell*, 39(2), 193.

Fitzgerald B, et al. (2021) A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. *Cell reports methods*, 1(5).